• Jae Guk Lee, Chuiyong Pak, Dong Kyu Oh, Ho Cheol Kim, Pil-Je Kang, Geun Dong Lee, Se Hoon Choi, Sung-Ho Jung, and Sang-Bum Hong.
• Department of Pulmonary and Critical Care, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
• J. Cardiothorac. Vasc. Anesth. 2022 Jun 1; 36 (6): 1686-1693.

ObjectiveRight ventricular heart failure (RVHF) is a critical complication in patients with respiratory failure, particularly among those who transitioned to lung transplantation using venovenous (VV) extracorporeal membrane oxygenation (ECMO). In these patients, both cardiac and respiratory functions are supported using venoarterial or venoarterial-venous ECMO. However, these modalities increase the risk of device-related complications, such as thromboembolism, bleeding, and limb ischemia, and they may disturb early rehabilitation. Due to these limitations, a right ventricular assist device with an oxygenator (Oxy-RVAD) using ECMO may be considered for patients with RVHF with VV ECMO.DesignA retrospective case series and literature review.SettingA single tertiary care university hospital.ParticipantsThe study comprised lung transplantation candidates on ECMO bridging who developed right-sided heart failure.InterventionsAn RVAD with ECMO.Measurements And Main ResultsOf eight patients who underwent the study protocol, seven were bridged successfully to lung transplantation (BTT), and all patients with BTT were discharged, with a 30-day survival rate of 100% (7/7 patients). The 180-day survival rate was 85% (6/7 patients).ConclusionsThe study suggested that Oxy-RVAD using ECMO may be a viable option for bridging patients with RVHF to lung transplantation.Trial RegistrationRetrospectively registered.Copyright © 2021 Elsevier Inc. All rights reserved.

14 keywords...

hide…